Gusacitinib Report issue

Biological Experimental
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
  • InChIKey: NLFLXLJXEIUQDL-UHFFFAOYSA-N
  • Mol. Mass: 460.54
  • ALogP: 2.55
  • ChEMBL Molecule:
    gusacitinib  
More Chemistry

Pharmacology

Alternative names

asn002 | asn-002

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Basal Cell Nevus Syndrome (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Dermatitis, Atopic (Phase 2)

Digital Dermatitis (Phase 2)

Eczema (Phase 1)

Healthy Volunteers (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, B-Cell (Phase 1/Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Skin Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue